DMD # 74609
Introduction DMD # 74609 and M11 being the two major products observed, suggesting the de-glucuronidation of M9 to form EPAC via gut microbiota. This finding supports the likely involvement of M9 in the EHC of EPAC.
It has been increasingly recognized by both regulatory agencies and pharmaceutical industry that drug transporters play important roles in absorption and disposition of a drug and therefore clinical drug-drug interactions (DDIs) (Giacomini et al., 2010) . Numerous research articles investigating new chemical entity (NME)-transporter interactions have been published since the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) released the draft guidance on evaluation of drug interactions of investigational drugs (FDA, 2012; EMA, 2012) in 2012. However, the publications investigating metabolite-transporter interactions are still in their infancy. While metabolites are less likely to cause DDIs via inhibition of cytochrome P450 enzymes due to increased polarity and metabolic stability, reduced passive membrane permeability of metabolites makes them more susceptible to interactions with drug transporters (Zamek-Gliszczynski et al., 2014) . In the present study, in order to gain a more complete understanding of the underlying mechanisms of the disposition and pharmacokinetics of EPAC, we adopted a comprehensive strategy to determine the in vitro interactions of both EPAC and its metabolites with the major drug transporters (P-pg, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, and OCT2) and evaluate their potential as a perpetrator to cause transporter-mediated clinical DDIs employing a range of in vitro models. It has been demonstrated that MRP2 and MRP3 are critical efflux transporters in the disposition of many glucuronide conjugates in hepatocytes via biliary excretion and basolateral efflux of these conjugates, respectively (Zamek-Gliszczynski et al., 2006; de Waart et al., 2009; Köck and Brouwer, 2012; Zhang et al., DMD # 74609 or three days by treatment with 0.05% trypsin containing 1 μM EDTA. For uptake assays, CHO and Flp-In™-293 cells were seeded at a density of 4,000-10,000 cells/well in 96-well microplates coated with collagen I (CHO cells) or poly-L-lysine . Uptake experiments were carried out 24 to 48 hours post-seeding when cells were at least 90% confluent. For OATP1B1, OATP1B3, and OAT3 transfected cells, the cells were treated with 5 mM sodium butyrate for 24 hours before the experiment to increase the expression of transfected transporters (Gui et al., 2008) .
Summary of In Vitro Models Used in the Present Article
For clarification of the choices of each in vitro model used to characterize the interactions of EPAC and its major metabolites with the drug transporters tested in this study, a summary table outlining the in vitro models, transporters, assay types, tested compounds, and primary purposes of using the individual models has been provided (see Table 1 ).
Transcellular Transport Assays in Caco-2 and MDCKII Cells
The transcellular transport studies in Caco-2 and MDCKII cells were carried out in house and the transcellular transport studies in transporter knock-out Caco-2 cells (MDR1/MRP2 and BCRP/MRP2 double-knockout) were conducted at BioReliance Corporation (Rockville, MD) under a service contract. All these studies were conducted by following similar procedures.
Briefly, on the day of study, after cell culture medium was removed, cells were rinsed with HBSS (pH 7.4) and equilibrated for 10 min before the experiment. Transepithelial electrical resistance (TEER) was measured to ensure the integrity of the cell monolayers. For Caco-2 apparent permeability (P app ) assay, digoxin (5 μM, positive control P-gp substrate), EPAC, M9, M11, or M12 at 50 μM in HBSS was added to the donor chamber (apical side), while HBSS solution with 4% BSA was added in the receiver chamber (basolateral side). For bidirectional transport assays that were conducted in Caco-2 and MDCKII cells, digoxin, prazosin (positive control BCRP substrate), EPAC, M9, M11, or M12 at predetermined 
concentrations in HBSS buffer
This article has not been copyedited and formatted. The final version may differ from this version. without BSA were placed in either apical (A) or basolateral (B) side as donor chambers, while fresh HBSS buffer without BSA was placed in receiver chambers. The 24-well transwell plates were incubated at 37°C for 120 minutes. At the end of the incubation, 0.1 ml of sample was removed from the receiver and donor chambers, and an equal volume of acetonitrile was added to the sample for protein precipitation. The supernatant was collected after centrifugation for LC-MS/MS analysis.
Vesicular Uptake Studies using Membrane Vesicles Containing Human Efflux Transporters
The substrate studies of M9 for efflux transporters MRP2, MRP3, and BCRP were performed at BioReliance Corporation (Rockville, MD) under a service contract using inside-out membrane vesicles generated from the mammalian cells stably-expressing human BCRP, MRP2, or MRP3. Briefly, membrane suspensions were added to assay media on ice and dispensed into a 96-well plate (25 µg total membrane protein per well). Following a pre-incubation at 37ºC for 5 min, M9 (1-100 µM) was incubated for 8 min at 37ºC along with either 4 mM ATP or AMP (as negative control) in the presence or absence of positive control inhibitor of MRP2 (400 µM benzbromarone), MRP3 (1 mM sulfasalazine), or BCRP (1 µM Ko143). Positive control substrate of MRP2 (50 µM estradiol 17-β-glucuronide (E 2 17βG)), MRP3 (50 µM E 2 17βG) or BCRP (1 µM estrone 3-sulfate) and negative membrane control assays were carried out in the same plate. The reactions were stopped by adding ice-cold washing buffer. The reaction mixture was then transferred to a filter plate, and the liquid was removed under vacuum using a cell harvester. The filters were dried and subsequently analyzed by LC-MS/MS. Results were calculated as ATP-dependent transport and were expressed as pmol/min/mg protein. A rate of uptake for test compound ≥ 1.5-2 fold (relative to the AMP control) or 2 fold with inhibitor are considered a positive result.
Determination of EPAC and its Metabolites as Substrates of Human Hepatic Uptake Transporters
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The potential for EPAC and its major metabolites to be a substrate of human hepatic uptake transporters OATP1B1 and OATP1B3 were determined using CHO cells stably transfected with OATP1B1 or OATP1B3. Pitavastatin was included as positive control substrate in the uptake experiments for both OATP1B1 and OATP1B3. These assays were conducted at 37°C using a 24-well format. After cell culture medium was removed, cells were washed once with prewarmed Krebs-Henseleit (KH) buffer (142 mM NaCl, 23.8 mM NaHCO 3 , 4.83 mM KCl, 0.96 mM K 2 HPO 4 , 12.5 mM HEPES, 1.53 mM CaCl 2 , and 1.2 mM MgSO 4 , pH 7.4). Uptake was initiated by adding 250 µl of KH buffer containing either the test compound (5 or 10 µM) or pitavastatin (0.5 µM). Cells were then incubated at 37°C for 1, 3, or 5 min (time-dependence studies). After the incubation, the uptake solution was rapidly aspirated and the cells were rinsed twice with 500 µl of ice-cold phosphate buffered saline (PBS) to stop uptake process. EPAC, M9, M11, M12, or pitavastatin that was accumulated in the cells was extracted by adding 250 µl of lysis solution (70:30 methanol:water (v:v) ) to each well. Following shaking the plate for 30 min, the cells were scraped briefly to maximize recovery of the samples. Cell lysate was centrifuged for 10 min at 13,000 rpm at 4°C. The supernatant was transferred to a 96-well plate for analysis using LC-MS. Protein amount was quantified using BCA protein assay kit (Pierce Biotechnology) and the plate for protein quantification was read on an Enspire Multilabel Reader (PerkinElmer, Waltham, MA).
Determination of EPAC and its Metabolites as Inhibitors of Human Uptake Transporters
The potential for EPAC and its major metabolites to inhibit the transport of probe substrates for human uptake transporters OATP1B1, OATP1B3, OAT1, OAT3, and OCT2 were determined using CHO or Flp-In™-293 cells stably transfected with each correspondent transporter. EPAC, M9, M11, or M12 was dissolved in DMSO with final concentrations between 0.13 and 300 µM.
Positive control inhibitors were 100 µM cerivastatin (OATP1B1), 10 µM cyclosporin A (OATP1B3), 200 µM benzbromarone (OAT1), 100 µM probenecid (OAT3), and 100 µM verapamil (OCT2). These assays were conducted at 37°C using a 96-well format with This article has not been copyedited and formatted. The final version may differ from this version. were then incubated at 37°C for designated time. After the incubation, the uptake solution was rapidly aspirated and the cells were rinsed twice with 100 µl of ice-cold PBS to stop uptake process. Cells were solubilized by adding 50 µl of 0.2 N NaOH and incubating for 15 min at 37ºC. Cell lysate was transferred to a white solid-bottom 96-well plate, and then 150 µl of MicroScint-40 scintillation cocktail was added to each well. After 3 hours incubation in the dark at room temperature, radioactivity was determined by using a MicroBeta ™ Microplate
Scintillation Counter (PerkinElmer, Waltham, MA).
LC-MS/MS Analysis
Samples containing EPAC, M11, M12, digoxin, nadolol, metoprolol, prazosin or pitavastatin from transcellular transport and uptake experiments were analyzed by using a Shimadzu LCMS- City, CA) operating in positive ionization mode with MRM transitions: m/z 614.2 → 438.0.
Chromatographic peaks were integrated and quantitative analysis was performed using Analyst software (version 1.4.1).
Data Analysis
Apparent permeability coefficient (P app ) values from transcellular transport studies were determined using the following equation:
where the flux rate (F, mass/time) is calculated from the slope of cumulative amounts of compound of interest on the receiver side, SA is the surface area of the cell membrane, VD is the donor volume and MD is the initial amount of the solution in the donor chamber. The efflux ratio (ER) from Caco-2 and MDCKII studies was calculated as the ratio of the P app measured in the B-A direction divided by the P app in the A-B direction. BCRP-mediated net efflux was determined by dividing the ER obtained from MDCKII-BCRP cells by the ER from MDCKIIcontrol cells.
The IC 50 values for inhibition of digoxin and prazosin transport by test compound from Caco-2 and MDCKII studies were determined by fitting the curve onto the net efflux ratio versus concentrations of test compound using a dose-response method from Prism 6.02 (2007, GraphPad, San Diego, CA) . The IC 50 value for uptake transporters was defined as the concentration of inhibitor needed to inhibit transport of the probe substrate by 50% and was determined using Prism 6.02. The degree of inhibition of OATP1B1 or OATP1B3 in humans was estimated by a static model using the R value (Hirano et al., 2006; Giacomini et al., 2010) , which represents the ratio of the uptake clearance in the absence of inhibitor to that in the presence of inhibitor:
This article has not been copyedited and formatted. The final version may differ from this version. where I in,max is the estimated maximum inhibitor concentration at the inlet to the liver, C max is the maximum systemic plasma concentration of inhibitor, Dose is the inhibitor dose, F a F g is the fraction of the dose of inhibitor which is absorbed, k a is the absorption rate constant of the inhibitor, and Q h is the hepatic blood flow rate in humans (1500 ml/min). Statistical analysis was conducted using a Student t test for comparing two treatments. A P value < 0.05 was considered significant.
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Results

Physicochemical Properties of EPAC and Its Metabolites
The absorption, distribution, metabolism, and excretion (ADME) of drugs and metabolites are profoundly influenced by their physicochemical properties such as molecular size, lipophilicity, polarity, and membrane permeability. The molecular weight, LogP, polar surface area (PSA), and apparent permeability values for EPAC, M9, M11, and M12 were summarized in Table 2 .
While the Caco-2 permeability values were moderate for EPAC, M11, and M12 ranging from 3.2 to 9.3 x 10 -6 cm/s, the value of M9 was very low (< 0.1 x 10 -6 cm/s) ( Table 2 ). This is expected because M9 as a direct glucuronide conjugate is more hydrophilic and polar with a low LogP value (-2.1) and a high PSA value (264).
Pharmacokinetic Profiles of EPAC in Human Subjects Suggesting EHC
After multiple twice daily oral dosing of 300 mg EPAC, the steady state plasma concentrationtime profiles of EPAC in 5 subjects (5 out of 17 subjects; 29%) exhibited distinct secondary peaks at approximately 4 h postdose ( Fig. 2 ), suggesting EHC of EPAC.
Evaluation of EPAC and Its Metabolites as P-gp and BCRP Substrates
Evaluation of EPAC and its metabolites as substrates of P-gp and BCRP was conducted in Caco-2 cell and BCRP-transfected MDCKII cell monolayers, respectively. Bi-directional transport experiments in Caco-2 cells indicated that the B-A/A-B efflux ratio (ER) of digoxin was 25. This ratio decreased to unity with the addition of the P-gp inhibitor CSA, indicating that P-gp expressed in the Caco-2 cells were functionally active. In the presence of CSA, the ER of EPAC was partially reduced (< 50%) (Fig. 3A ), suggesting that P-gp contributes to the efflux of EPAC and other transporters may also play a role in the efflux of EPAC in Caco-2 cell monolayers.
The ER of M9 was 2.5 and 1.9 at 1 or 20 μM, respectively, suggesting that the efflux of M9 in
Caco-2 cells is minimal and it is unlikely a P-gp substrate ( M12 at each concentration were below 2 (Fig. 3 , C and D), indicating that neither M11 nor M12
is a substrate of P-gp.
The ratio of ER of EPAC in BCRP-MDCKII cells to that in control-MDCKII cells (ER BCRP /ER control ) was 35 and 27 at 3 and 300 μM, respectively, indicating that EPAC is a substrate of BCRP and the efflux mediated by BCRP was not saturated at 300 μM (Fig. 3E ). The ER BCRP /ER control values of M11 were 93 and 48 at 10 and 300 μM, respectively, which suggests that M11 is a substrate of BCRP and its efflux mediated by BCRP was not saturated at 300 μM (Fig. 3G ). The ER BCRP /ER control values of M12 (1-300 μM) were around unity, indicating that M12 is not a substrate of BCRP ( Fig. 3H ). Because the permeability of M9 is very low and the bidirectional transport assay may underestimate the efflux ratios of low-permeability compounds (Brouwer et al., 2013) , a vesicular uptake assay using membrane vesicles containing BCRP was carried out to determine whether M9 is a substrate of BCRP. The uptake rates of M9 into BCRP-expressing membrane vesicles in the presence of ATP, AMP, or combination of ATP and Ko143 were 115, 60.2, and 53.5 pmol/min/mg protein, respectively (Fig. 3F ). This result implies that M9 is a substrate of BCRP.
To further evaluate the relative contribution of P-gp and BCRP in the efflux of EPAC in Caco-2 cells, an additional study was conducted in MDR1/MRP2 double KO and BCRP/MRP2 double KO Caco-2 cell lines. It has been demonstrated that these KO cell lines derived from Caco-2 cells (C2BBe1 clone) are similar to the wild type Caco-2 cells with respect to growth rate, morphology, differentiation, tight junction formation, passive permeability of model compounds, and stability of phenotype (Sampson et al., 2015) . Two control substrates, digoxin (P-gp substrate) and estrone sulfate (BCRP substrate), were used in this study to ensure the validity of these KO models. As expected, verapamil (positive control inhibitor of P-gp) completely 100% in P-gp/MRP2 KO cells. In addition, the ER of digoxin was not reduced by double KO of BCRP and MRP2 (Fig. 4D ) and the ER of estrone sulfate was not reduced by double KO of Pgp and MRP2 (Fig. 4B) , confirming the function of P-gp and BCRP proteins in these KO cell lines and the specificity of KO of the individual efflux transporters. As shown in Figure 4 , EPAC exhibited much higher efflux in the parental (ER = 24) and the P-gp/MRP2 KO cell lines (ER = 18) than BCRP/MRP2 KO cell line (ER = 4.2), indicating that BCRP may play a more important role in the efflux of EPAC in Caco-2 cells than P-gp. Verapamil partially inhibited efflux of EPAC in the parental cells (ER reduced from 15 to 10, 33% inhibition), and completely inhibited efflux in BCRP/MRP2 KO cells (ER reduced from 4.2 to 1.4) (Fig. 4C ). The efflux of EPAC was inhibited by Ko143 (ER reduced from 24 to 5.5, 77% inhibition) in the parental cells to a greater extent than verapamil, and completely inhibited by Ko143 in the P-gp/MRP2 KO cells (ER reduced from 18 to 1.1) (Fig. 4A) . These results suggest that EPAC is a substrate of both P-gp and BCRP, although it appears that BCRP may have more pronounced effect on the efflux of EPAC in Caco-2 cells.
Evaluation of EPAC and Its Metabolites as OATP1B1 and OATP1B3 Substrates
Given the important roles of OATP1B1 and OATP1B3 in the hepatic uptake of drugs and metabolites in humans, in vitro uptake studies were performed to investigate whether EPAC and its metabolites are substrates of these two uptake transporters by using CHO cells transfected with human OATP1B1 or OATP1B3. to 1.7-fold) of that in control cells (Fig. 5, C , D, G and H) , it is unlikely that M11 and M12 are substrates of OATP1B1 and OATP1B3.
As per the decision tree in the FDA guidance (FDA, 2012) , additional experiments were performed using cerivastatin as a positive control inhibitor of OATP1B1 and OATP1B3 to confirm whether EPAC and M9 are substrates of OATP1B1 and OATP1B3. Pitavastatin was used as a positive control substrate in these experiments. The uptake of pitavastatin into OATP1B1-or OATP1B3-transfected cells was significantly reduced by cerivastatin, indicating the effectiveness of the inhibitor treatment (Fig. 6, C , D, G, and H). The uptake of EPAC into OATP1B1-or OATP1B3 transfected cells in the presence of cerivastatin was not significantly different from that of the vehicle control, implying that EPAC is not a substrate of OATP1B1 or OATP1B3 (Fig. 6, A and B) . In contrast to EPAC, cerivastatin reduced the uptake of M9 into OATP1B1-and OATP1B3-transfected cells by 91% and 81%, respectively (Fig. 6 , E and F).
These results confirm that M9 is a substrate of both OATP1B1 and OATP1B3.
Evaluation of M9 as a Substrate for MRP2 and MRP3
Because M9 is a glucuronide conjugate of EPAC with low membrane permeability and exhibited strongly inhibited the accumulation of M9 in the MRP3-containing vesicles (> 90% inhibition) (Fig. 7B) . These results clearly indicate that M9 is a substrate for MRP2 and MRP3.
Evaluation of EPAC and Its Metabolites as P-gp and BCRP Inhibitors
To determine whether P-gp is inhibited by EPAC and its metabolites, the ER of digoxin in Caco-2 cells was examined in the absence or the presence of various concentrations of EPAC, M9, M11 or M12. The ER of digoxin decreased in the presence of EPAC in a concentrationdependent manner. At 500 μM EPAC, the ER of digoxin reduced by only 45%, suggesting that the IC 50 of EPAC is greater than 500 μM (Table 3) . No significant decrease in the ER of digoxin was observed in the presence of M9, M11, or M12 over the concentrations between 0 and 300 μM, therefore these metabolites are not inhibitors of P-gp (Table 3 ).
The potential of EPAC and its metabolites to inhibit BCRP was determined in MDCKII-BCRP cell line. Prazosin was used as a prototype substrate of BCRP (Ni et al., 2010) , and Ko143 was used as a BCRP inhibitor (Allen et al., 2002) . The ER BCRP /ER control value of prazosin was not reduced in the presence of various concentrations of EPAC or M9 (0-300 μM), which indicates that EPAC and M9 are not inhibitors of BCRP. The BCRP-mediated efflux of prazosin was slightly reduced in the presence of various concentrations of M11 (0-300 μM), and the IC 50 value was greater than 300 μM. M12 inhibited the BCRP-mediated efflux of prazosin significantly with an IC 50 value of 32 μM (Table 3) . Overall, the potential of both EPAC and its metabolites to cause clinical DDIs via inhibition of P-gp or BCRP is low because the ratios of I 1 /IC 50 are below 0.1 and the ratios of I 2 /IC 50 are below 10 based on the FDA guidance on DDI evaluation (Table 4) .
Evaluation of EPAC and Its Metabolites as Inhibitors of OATP1B1, OATP1B3, OAT1,
OAT3 and OCT2
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The calculated ratios of total C max /IC 50 for hepatic uptake transporters OATP1B1 and OATP1B3
and the ratios of unbound C max /IC 50 for renal uptake transporters OAT1, OAT3, and OCT2 are less than 0.1 except that the ratios of total C max /IC 50 of M9 and M11 for OATP1B3 are greater than 0.1 (0.38 and 0.11, respectively) ( Tables 5 and 6 ). Because the ratios of total C max /IC 50 of M9 and M11 for OATP1B3 are greater than 0.1, the R values of M9 and M11 were calculated using extrapolation (Table 5) by following the decision tree in the FDA guidance (FDA, 2012). 
Discussion
In the current investigation, we took a comprehensive approach to determine the in vitro interactions of both EPAC and its major metabolites with key drug transporters involved in drug absorption and disposition, and assessed their potential to cause transporter-mediated DDIs. By following this approach, we were able to understand the molecular mechanisms of the disposition of both EPAC and its metabolites in humans and elucidate the complex process of metabolism, transport, and enzyme-transporter interplay. With such important information, our understanding of the underlying mechanisms of the pharmacokinetics of EPAC can be substantially improved and the ongoing clinical development of this promising investigational drug can benefit from the knowledge derived from this investigation.
EPAC is found to be a substrate of P-gp and BCRP, which are key efflux transporters expressed in human intestine, brain, liver, and kidney. In a clinical pharmacokinetic study, the exposure of EPAC increased in a dose-proportional manner in the range of 50-400 mg BID.
Therefore, the role of efflux transporters, including P-gp and BCRP, in limiting oral absorption of EPAC might be insignificant at the doses (up to 300 mg BID) used in the clinical development.
While the uptake of EPAC was higher in CHO cells expressing OATP1B1 or OATP1B3 than that in control cells, the uptake of EPAC was not significantly inhibited by an inhibitor of OATP1B, cerivastatin. Therefore, EPAC may not be a substrate for OATP1B1 or OATP1B3. Given its moderate membrane permeability, the major route for EPAC to enter hepatocytes may be through passive diffusion.
The involvement of EHC in the disposition of EPAC is suggested by the distinct secondary peaks in the profiles of EPAC in healthy human subjects (Fig. 2) . We postulated that the glucuronide conjugate M9 (the most abundant circulating metabolite) may participate in the EHC of EPAC because glucuronide metabolites are frequently shown to be involved in EHC of a drug.
Thus, the interactions of M9 with hepatic drug transporters were investigated to gain insight of
This article has not been copyedited and formatted. The final version may differ from this version. the disposition of M9 in the liver and its implication for the pharmacokinetics of EPAC. While EPAC, M11, and M12 exhibit moderate permeability, the more hydrophilic M9 displays very low permeability in Caco-2 cells (Table 2) , making it heavily reliant on interactions with transporters to cross cell membranes (Zamek-Gliszczynski et al., 2014). Among the major canalicular efflux transporters (MRP2, BCRP, and P-gp) responsible for biliary excretion of drugs and metabolites, MRP2 (Fig. 7A) and BCRP (Fig. 3F) likely participate in the biliary excretion of M9. Given its low permeability and high systemic exposure, we suspected that M9 may be excreted to blood by the basolateral efflux transporter MRP3 following its formation in hepatocytes. Our results indeed confirmed that M9 is a MRP3 substrate (Fig. 7B) . Whether M9 is also a substrate of other basolateral efflux transporters (such as MRP4) remains to be determined. M9 is also
shown to be taken up by OATP1B1 and OATP1B3, the major uptake transporters in the basolateral membrane of hepatocytes (Fig. 5, B and F) , suggesting that the circulating M9 in the blood relies on uptake transporters to enter hepatocytes for its biliary excretion.
As illustrated in Figure 8 , our data suggest that once formed within the hepatocytes by UGT1A9 enzyme, M9 relies on interactions with the canalicular efflux transporters MRP2 and BCRP to be excreted into the bile, the basolateral efflux transporter MRP3 to be excreted into the blood, and the basolateral uptake transporters OATP1B1 and OATP1B3 to be transported from the blood back into the hepatocytes for its subsequent biliary excretion. By preventing saturation of the canalicular efflux transporters in the upstream hepatocytes, these basolateral transporters conjugates, such as bilirubin glucuronide (Iusuf et al., 2012) and sorafenib glucuronide (Vasilyeva et al., 2015) . Vasilyeva et al hypothesized (Vasilyeva et al., 2015) that considering the broad substrate specificity of these hepatic transporters (MRPs and OATPs), other xenobiotics undergoing hepatic glucuronidation can be subject to the hepatocyte hopping process similar to that of sorafenib glucuronide. Although more studies are needed in this emerging area in the future, the transporter-mediated disposition of glucuronide metabolites of EPAC, ezetimibe, and diclofenac in the liver might support this hypothesis. Similarly, the MPA exposure in the patients carrying a genetic variant of OATP1B3 was lower than that in the patients carrying wildtype OATP1B3 because the hepatic uptake of MPAG was impaired due to the reduced function of the OATP1B3 variant, and thus the biliary excretion of MPAG was decreased, resulting in the decreased EHC of MPA (Picard et al, 2010) .
This article has not been copyedited and formatted. The final version may differ from this version. The potential of EPAC and its major metabolites to cause transporter-mediated clinical DDIs was also evaluated in the present study. Based on their inhibitory potency and human exposures, the risk of EPAC, M9, M11 and M12 to cause clinical DDIs via inhibition of Pgp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2 was estimated to be low (Tables 4-6 ). It is worth noting that some challenges exist in evaluating the risk of transporter-mediated DDI caused by metabolites. One of these challenges is estimation of I 2 concentration (theoretical maximum concentration in the intestine). Usually, metabolite concentrations at the intestinal level are not readily calculable because the liver is the major site for metabolism. In the case of EPAC metabolism, M11 is formed from EPAC by the gut flora and majority of M9 is moved from the bile to the intestine where M9 can be de-conjugated to form EPAC. Consequently, it is difficult to determine the maximum intestinal concentrations of M11 and M9. Under the most conservative consideration, if all EPAC molecules following oral dose of 300 mg (the highest dose in the clinical development) are converted to M11 (in the intestine) or M9 (in the liver) with all M9 molecules moving to the intestine, the I 2 concentrations of M11 and M9 would be the same as that of EPAC (2740 µM). Thus, the ratios of I 2 /IC 50 of both metabolites would be less than 10, indicating low risk of DDIs due to inhibition of P-pg or BCRP. When the R value method is used to evaluate OATP1B-mediated DDIs, estimation of I in,max of metabolites is another challenge because some parameters, such as k a , F a , F g and dose, of metabolites are difficult to estimate. In the cases of M9 and M11, the R values were calculated based on total C max instead of I in,max , therefore the R values may be underestimated.
In conclusion, the in vitro interactions of both EPAC and its major metabolites with key drug transporters involved in drug absorption and disposition were evaluated in this study. EPAC is shown to be a substrate for BCRP and P-gp, but not a substrate for OATP1B1 or OATP1B3.
Given the likely involvement of M9 in the EHC of EPAC observed in humans, we also identified the transporters involved in the disposition of M9 (EPAC glucuronide) in the liver. M9 is a substrate for multiple uptake (OATP1B1 and OATP1B3) and efflux (MRP2, MRP3, and BCRP)
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